Market news

Johnson & Johnson reports Q3 earnings Oct. 13; EPS seen at $2.48, revenue $25.31B. Analysts are mostly bullish after positive Tremfya and Carvykti data.

Johnson & Johnson (NYSE:JNJ) reported new long term IMAAVY data in generalized myasthenia gravis, including adolescent outcomes. The company said adolescents with gMG on IMAAVY showed sustained disease control and reduced reliance on corticosteroids, with no new safety signals. Survey findings from healthcare professionals indicated IMAAVY may address unmet needs for more consistent symptom management in gMG treatment. The new IMAAVY findings in adolescent gMG sit alongside broader shifts...

In the latest trading session, Johnson & Johnson (JNJ) closed at $267.66, marking a -1.58% move from the previous day.

Analysts expect Johnson & Johnson's Q3 FY2027 sales to be in line, but EPS to be below consensus due to IPR&D dilution.

Johnson & Johnson reports Q3 earnings Oct 13. Explore key growth drivers in oncology & Tremfya, plus valuation risks with a premium P/E. Click for this JNJ update.

Gilead Sciences, Inc. (NASDAQ:GILD) and Johnson & Johnson (NYSE:JNJ) offer investors two very different versions of pharmaceutical growth. Gilead is expanding faster, powered by an HIV franchise that continues to gain momentum, while Johnson & Johnson isn’t growing as quickly, but its portfolio stretches across pharmaceuticals and MedTech, giving it more ways to absorb weakness […]

Johnson & Johnson (NYSE:JNJ) reported new clinical data for TECVAYLI plus DARZALEX FASPRO, CARVYKTI, and TREMFYA in multiple myeloma and axial psoriatic arthritis. Early line multiple myeloma data suggest TECVAYLI plus DARZALEX FASPRO could align patient mortality risk with that of the general population. CARVYKTI results highlight treatment-free remissions lasting five years in relapsed or refractory multiple myeloma, while TREMFYA data support an axial psoriatic arthritis label...

Johnson & Johnson shares key clinical trial results for Tremfya in psoriatic arthritis and five-year Carvykti data in multiple myeloma.

Johnson & Johnson (NYSE:JNJ) said its Tremfya treatment significantly improved spinal pain and stiffness in adults with axial psoriatic arthritis in a Phase 4 study. The company said Tremfya met the study’s primary endpoint at week 24, showing greater improvement than placebo on a disease...

It was reported on September 11 that Apollo Global Management, Inc. (NYSE:APO) is in discussions to acquire Johnson & Johnson (NYSE:JNJ)’s orthopedics business, DePuy Synthes, in a potential transaction valuing the unit at close to $20 billion, according to Bloomberg. The unit, which J&J previously announced plans to separate within an 18-to-24-month timeframe, generated $9.3 […]

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

Key TakeawaysJohnson & Johnson’s MedTech segment, the business OTTAVA sits inside, grew from $7. 89 billion to $8.

Players: Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker, Zimmer Biomet. Profile covers competitors, segments, regional shares, trends and opportunities. Minimally Invasive Robotic Surgical System Market Minimally Invasive Robotic Surgical System Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Minimally Invasive Robotic Surgical System Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Minimally Invasive Robotic Surgical System Market to Reach $18.15 Bil

Johnson & Johnson recently reported positive topline Phase 3 results for CAPLYTA (lumateperone) in adults with bipolar I disorder experiencing manic episodes, showing rapid and statistically significant symptom reduction versus placebo, while also highlighting progress across its broader neuropsychiatry portfolio. The data suggest CAPLYTA could potentially treat both depressive and acute manic episodes in bipolar I disorder, meaningfully broadening its clinical role if future regulatory...

Johnson & Johnson (NYSE: JNJ) received FDA approval for ICOTYDE (icotrokinra) to treat moderate to severe plaque psoriasis in the U.S. ICOTYDE targets the IL-23 receptor and is in Phase III clinical trials for a potential psoriatic arthritis indication. The new therapy extends Johnson & Johnson's immunology pipeline beyond oncology and MedTech into chronic inflammatory skin and joint conditions. The ICOTYDE psoriasis approval and psoriatic arthritis Phase III program deserves weighing...

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.

Johnson & Johnson announces positive Phase 3 results for CAPLYTA, showing rapid reduction in bipolar I disorder manic symptoms.

Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings analysts expect.

JNJ's growth gets a boost from new drug launches and pipeline wins, but Stelara's patent loss and MedTech headwinds remain key risks.

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

In the most recent trading session, Johnson & Johnson (JNJ) closed at $270.22, indicating a +1.1% shift from the previous trading day.

Johnson & Johnson (NYSE:JNJ) Executive Vice President and Chief Financial Officer Joe Wolk said the company sees a path to growth above its previously stated 5% to 7% long-term range, supported by its pharmaceutical pipeline, medical technology portfolio and capital flexibility. Speaking at a Deuts

Contineum Therapeutics, Inc. (NASDAQ:CTNM) shares are trading lower on Tuesday as Phase 2 results from a key study disappoint. The pullback lines up with a risk-off tone in futures, but the company-specific clinical update appears to be the main driver. CTNM Stock Drops After Phase 2 MOONLIGHT-1 Results The company said its Phase 2 MOONLIGHT-1 trial did not meet its primary efficacy endpoint for JNJ-5120 / PIPE-307 in major depressive disorder. JNJ-5120/PIPE-307 is being developed by Johnson & J

Apollo Global Management, Inc. (NYSE:APO) is reportedly in talks to acquire Johnson & Johnson (NYSE:JNJ) DePuy Synthes orthopedics business in a transaction that could value the unit at close to $20 billion, according to Bloomberg, as reported by Reuters. J&J generated $9.3 billion of revenue from the orthopedics business in 2025, making the potential transaction […]

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medicines, medical devices and pipeline programs to support accelerating growth through the end of the decade. Speaking at a Morgan Stanley e

These alleged talks come as J&J considers what direction to take DePuy Synthes in as it spins out from the wider business.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

Apollo is in discussions to acquire DePuy Synthes, which generated $9.3 billion in sales last year and could also be spun off as a public company

Johnson & Johnson (NYSE:JNJ) shares rose 1. 3% to $268.

The drugmaker is the latest to impose a reporting requirement on 340B providers, saying stricter guardrails are needed to prevent duplicative discounts.

Johnson & Johnson, Coca-Cola and Exxon Mobil have been highlighted in this Investment Ideas article.